CorMedix
CRMD
34 hedge funds and large institutions have $4.26M invested in CorMedix in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
3% more funds holding
Funds holding: 33 → 34 (+1)
0.3% less ownership
Funds ownership: 2.83% → 2.53% (-0.3%)
3% less capital invested
Capital invested by funds: $4.38M → $4.26M (-$117K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $56K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$291K |
| 2 |
VF
Virtu Financial
New York
|
+$72.7K |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$48.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$35.4K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$337K |
| 2 |
BG
Bollard Group
Boston,
Massachusetts
|
-$209K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$34.6K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$28.7K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$17.2K |
CRMD Hedge Fund Activity: Q4 2017 in Review
34 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2017, worth a combined $4.26M — down 2.7% from $4.38M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRMD positions and 4 closed out — a net gain of 3 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $291K. The largest seller was Sabby Management, exiting entirely with an estimated $337K sold.
- 34 institutional investors held CorMedix (CRMD) as of Q4 2017, up from 33 in Q3 2017.
- Funds reported $4.26M of CorMedix stock for Q4 2017, down 2.7% quarter-over-quarter.
- 7 funds opened new CorMedix positions in Q4 2017 and 4 closed out, a net change of +3 holders.
- The largest CorMedix buyer in Q4 2017 was Vanguard Group, an estimated $291K added.
- The largest CorMedix seller in Q4 2017 was Sabby Management, an estimated $337K sold.
Based on aggregated 13F filings for Q4 2017.